Donewell Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.50 Cr
- Paid Up Capital ₹ 2.25 Cr
- Company Age 17 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.11 M
- Satisfied Charges ₹ 2.00 Cr
- Revenue Growth 5.05%
- Profit Growth 102.53%
- Ebitda -4.89%
- Net Worth 0.50%
- Total Assets -1.17%
About Donewell Pharmaceuticals
Donewell Pharmaceuticals Private Limited (DPPL) is a Private Limited Indian Non-Government Company incorporated in India on 31 July 2007 and has a history of 17 years and six months. Its registered office is in Kamrup, Assam, India.
The Company is engaged in the Food And Beverages Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.50 Cr and a paid-up capital of Rs 2.25 Cr.
The company currently has active open charges totaling ₹1.11 M. The company has closed loans amounting to ₹2.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Bishu Kundu and Shubham Sharma serve as directors at the Company.
Company Details
-
Location
Kamrup, Assam, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232AS2007PTC008438
-
Company No.
008438
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
31 Jul 2007
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Shillong
Industry
Who are the key members and board of directors at Donewell Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bishu Kundu
|
Director | 02-Jul-2022 | Current |
|
Shubham Sharma
|
Director | 02-Jul-2022 | Current |
Financial Performance of Donewell Pharmaceuticals.
Donewell Pharmaceuticals Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 5.05% increase. The company also saw a substantial improvement in profitability, with a 102.53% increase in profit. The company's net worth moved up by a moderate rise of 0.5%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Donewell Pharmaceuticals?
In 2020, Donewell Pharmaceuticals had a promoter holding of 37.18% and a public holding of 62.82%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.11 Cr
₹2.00 Cr
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.11 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Sep 2022 | Hdfc Bank Limited | ₹1.11 M | Open |
| 16 Dec 2014 | United Bank Of India | ₹2.00 Cr | Satisfied |
How Many Employees Work at Donewell Pharmaceuticals?
Unlock and access historical data on people associated with Donewell Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Donewell Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Donewell Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
